Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance – Yahoo Finance
The authors are quick to point out that their findings should not be interpreted as a reason to avoid pregnancy. The signaling pathway usurped by cancer cells is not the cause of breast cancer. Rather, they said, it may worsen or accelerate a cancer caused by other factors, such as an underlying mutation or genetic predisposition. Our work doesnt speak to the actual cause of cancer.
For the original version including any supplementary images or video, visit http://www.newswise.com/articles/view/621598/?sc=rsmn
June: Topline data from the Phase III study of ofatumumab versus physician’s choice in patients with bulky fludarabine-refractory CLL showed that the study did not meet its primary endpoint. May: Announced that GSK has taken the decision to start Phase III studies of Biocutis Press Release subcutaneous ofatumumab in RRMS in 2015, and plans to file an Investigational New Drug application (IND) for a potential pivotal study of subcutaneous ofatumumab in NMO in 2014. May: Topline results from the Phase III study (ORCHARRD) of ofatumumab in combination with chemotherapy versus rituximab in combination with chemotherapy for relapsed or refractory DLBCL showed that the study did not meet its primary endpoint. April: The US FDA approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. Daratumumab August: Announced a Phase III study of daratumumab in combination with lenalidomide and dexamethasone compared to lenalidomide and dexamethasone alone as front line treatment for multiple myeloma patients who are not considered candidates for stem cell transplantation (SCT). The study is planned to start in the first half of 2015.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/genmab-announces-financial-results-first-151038098.html
Could venom from scorpions, snakes and bees stop the growth of some cancer cells? | Q13 FOX News
In camouflaging the whole toxin as a part of the nanoparticle, Pan said, it bypasses healthy cells and is attracted to only the cancer cells. In other words, its so tightly packed into the nanoparticle it doesnt leak out and cause other problems. Attached to the cancer cells, these nanoparticles with the synthesized venom can either slow down or stop cancer cell growth, and may ultimately stop the cancer from spreading. Particles in bee venom seem to specifically stop the cancer stem cells. Thats what we are interested in those are the cells responsible for metastasizing and also responsible for having the cancer cells grow back, Pan said.
For the original version including any supplementary images or video, visit http://q13fox.com/2014/08/12/could-venom-from-scorpions-snakes-and-bees-stop-the-growth-of-some-cancer-cells/